ImmunityBio, Inc. (NASDAQ:IBRX) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus: Seven analysts give ImmunityBio an average rating of "Moderate Buy" (1 sell, 5 buy, 1 strong buy) with a mean 12‑month price target of $14.40.
• Regulatory and legal risk: The company has an FDA warning letter related to Anktiva and faces multiple securities class actions (lead‑plaintiff deadline May 26, 2026), which could drive costly litigation, settlements and share volatility.
• Insider activity and ownership: Insiders own about 69.48% of the stock and sold 501,967 shares worth ~$4.47M over the last quarter, including large director sales at roughly $10–$12 per share.

Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $14.40.

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of ImmunityBio in a report on Monday, December 29th. The Goldman Sachs Group restated a "buy" rating on shares of ImmunityBio in a report on Monday, February 23rd. Piper Sandler restated an "overweight" rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. BTIG Research assumed coverage on shares of ImmunityBio in a report on Thursday, March 12th. They issued a "buy" rating and a $13.00 price objective on the stock. Finally, HC Wainwright raised their price objective on shares of ImmunityBio from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday, February 23rd.

Insider Buying and Selling at ImmunityBio

In related news, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Barry J. Simon sold 75,000 shares of ImmunityBio stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the sale, the director owned 2,850,821 shares in the company, valued at $34,238,360.21. This represents a 2.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 501,967 shares of company stock worth $4,466,412 over the last quarter. 69.48% of the stock is owned by company insiders.

Institutional Investors Weigh In On ImmunityBio

Several hedge funds and other institutional investors have recently bought and sold shares of IBRX. AQR Capital Management LLC raised its stake in ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company's stock worth $134,000 after acquiring an additional 29,297 shares in the last quarter. Creative Planning raised its stake in ImmunityBio by 9.2% during the 2nd quarter. Creative Planning now owns 62,028 shares of the company's stock worth $164,000 after acquiring an additional 5,231 shares in the last quarter. Cetera Investment Advisers raised its stake in ImmunityBio by 56.9% during the 2nd quarter. Cetera Investment Advisers now owns 18,551 shares of the company's stock worth $49,000 after acquiring an additional 6,731 shares in the last quarter. JPMorgan Chase & Co. raised its stake in ImmunityBio by 5.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,071,736 shares of the company's stock worth $2,829,000 after acquiring an additional 52,782 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of ImmunityBio by 11.8% during the second quarter. Legal & General Group Plc now owns 205,478 shares of the company's stock worth $542,000 after buying an additional 21,715 shares during the period. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Trading Up 2.4%

Shares of IBRX opened at $7.78 on Thursday. ImmunityBio has a twelve month low of $1.83 and a twelve month high of $12.43. The firm's fifty day simple moving average is $7.93 and its 200-day simple moving average is $4.65. The firm has a market capitalization of $8.00 billion, a price-to-earnings ratio of -20.47 and a beta of 0.13.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter. On average, analysts predict that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Analyst/valuation coverage highlights ANKTIVA‑driven Q1 2026 revenue updates that may underpin parts of ImmunityBio’s valuation; this could provide a counterweight to legal headlines if revenue trends remain intact. Assessing ImmunityBio Valuation
• Neutral Sentiment: Company founder pushed back on the FDA warning, saying an advertising claim at issue never aired — a defensive narrative that could blunt some reputational damage but does not remove regulatory or litigation risk. Founder Pushback
• Negative Sentiment: Multiple securities class actions have been filed alleging the company made materially misleading statements about Anktiva after an FDA warning letter; plaintiff firms (Hagens Berman and others) point to significant share declines and lost market cap as investor harm. This increases the chance of costly litigation, settlements, and distraction for management. Hagens Berman Notice
• Negative Sentiment: Dozens of plaintiff law firms are soliciting IBRX investors and reminding shareholders of a May 26, 2026 deadline to seek lead‑plaintiff status — a clustering of lawsuits and solicitations that typically raises legal costs, settlement risk and share volatility. Examples include Kessler Topaz, Kahn Swick & Foti, Glancy Prongay Wolke, Rosen, Berger Montague and others. Kessler Topaz Alert
• Negative Sentiment: Regulatory scrutiny (FDA warning letter) is central to the suits; any further FDA findings, enforcement actions, or negative clinical/regulatory updates for Anktiva would materially worsen downside risk for the stock and could impair commercialization prospects. Reminder/Deadline

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.